SLC2A1 and cancer: The regulatory mechanism of glycolytic flux in normal cells is subverted in cancer cells to inhibit rate-limiting steps and reengineer the glucose metabolism by inducing many glycolytic enzymes and transporters, such as HK2, GLUT1, and PDK15,19.